Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Payables (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Payables data on record, last reported at $15.6 million in Q3 2025.

  • For Q3 2025, Payables fell 21.4% year-over-year to $15.6 million; the TTM value through Sep 2025 reached $15.6 million, down 21.4%, while the annual FY2024 figure was $15.5 million, 1.48% up from the prior year.
  • Payables reached $15.6 million in Q3 2025 per SGMO's latest filing, up from $10.7 million in the prior quarter.
  • Across five years, Payables topped out at $22.4 million in Q4 2022 and bottomed at $8.0 million in Q3 2021.
  • Average Payables over 5 years is $14.8 million, with a median of $15.5 million recorded in 2023.
  • Peak YoY movement for Payables: crashed 55.4% in 2021, then skyrocketed 129.72% in 2022.
  • A 5-year view of Payables shows it stood at $9.8 million in 2021, then surged by 129.72% to $22.4 million in 2022, then tumbled by 31.93% to $15.3 million in 2023, then grew by 1.48% to $15.5 million in 2024, then increased by 0.46% to $15.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $15.6 million in Q3 2025, $10.7 million in Q2 2025, and $18.2 million in Q1 2025.